Please login to the form below

Not currently logged in
Email:
Password:

New registry to improve partnering

Thomson Reuters has launched The Outpartnering Registry, a resource helping biotech and pharma organisations find partnering opportunities

Thomson Reuters has launched The Outpartnering Registry, a resource helping biotechnology, pharmaceutical and academic organisations find partnering opportunities around the world.

The Outpartnering Registry is available free to all organisations with drugs in development. It enables authorised users to share essential information about their company and drug pipeline with potential partners. Ninety per cent of the world's top 50 pharmaceutical companies will have access to information in the registry via Thomson Pharma Partnering, which provides pipeline intelligence.

The Outpartnering Registry allows organisations to:

  • Indicate which of their programmes and drugs are available for partnering and, optionally, what type of partnership they are seeking in which regions of the world
  • Add and update partnering contacts together with links to LinkedIn profiles
  • Display attendance at partnering conferences and increase networking opportunities.

"Pharma companies need new and innovative ways to share the financial risk of developing drugs," said Mark Gordon, director of product strategy at Thomson Reuters. "This new initiative benefits both drug innovators, who can easily update their partnering information online, as well as in-licensors, who can quickly find assets available for partnering."

"The Outpartnering Registry from Thomson Reuters will make it easier for us to market products for our clients," said Damon Bowe, consultant at New Orleans BioInnovation Center. "The industry has expressed the need for this registry and it is an effective way for us to market inventions and to create partnerships between academia and industry."

For more information about The Outpartnering Registry, visit: go.thomsonreuters.com/outpartnering

21st June 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics